Clincosm LogoSign in Get a demo

Expanded Access to NanoDoce

Sponsor
NanOlogy, LLC (Industry)
Overall Status
Available
CT.gov ID
NCT04060628
Collaborator
US Biotest, Inc. (Industry)

Study Details

Study Description

Brief Summary

NanOlogy may consider offering expanded access to NanoDoce for patients who do not meet the enrollment criteria of clinical trials in progress.

Condition or Disease Intervention/Treatment Phase
  • Drug: NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension

Study Design

Study Type:
Expanded Access
Official Title:
Expanded Access to NanoDoce

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    Exclusion Criteria:

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • NanOlogy, LLC
    • US Biotest, Inc.

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    NanOlogy, LLC
    ClinicalTrials.gov Identifier:
    NCT04060628
    Other Study ID Numbers:
    • NANODOCE-EA
    First Posted:
    Aug 19, 2019
    Last Update Posted:
    Apr 11, 2022
    Last Verified:
    Apr 1, 2022
    Additional relevant MeSH terms:
    Urogenital Neoplasms
    Docetaxel

    Study Results

    No Results Posted as of Apr 11, 2022